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Choline kinase inhibitors EB-3D 
and EB-3P interferes with lipid 
homeostasis in HepG2 cells
Alberto sola-Leyva1, Luisa C. López-Cara2, pablo Ríos-Marco1, Antonio Ríos3, Carmen Marco1 
& María p. Carrasco-Jiménez1
A full understanding of the molecular mechanism of action of choline kinase α (ChoKα) inhibitors at 
the cell level is essential for developing therapeutic and preventive approaches for cancer. The aim 
of the present study was to evaluate the effects of the ChoKα inhibitors EB-3D and EB-3P on lipid 
metabolism in HepG2 cells. We used [methyl-14C]choline, [1,2-14C]acetic acid and [2-3H]glycerol as 
exogenous precursors of the corresponding phospholipids and neutral lipids. [Methyl-14C]choline was 
also used to determine choline uptake. Protein levels were determined by Western blot. Ultrastructural 
alterations were investigated by transmission electron microscopy. In this work, we demonstrate that 
EB-3D and EB-3P interfere with phosphatidylcholine biosynthesis via both CDP-choline pathway and 
choline uptake by the cell. Moreover, the synthesis of both diacylglycerols and triacylglycerols was 
affected by cell exposure to both inhibitors. These effects were accompanied by a substantial decrease 
in cholesterol biosynthesis, as well as alterations in the expression of proteins related to cholesterol 
homeostasis. We also found that EB-3D and EB-3P lowered ChoKα protein levels. All these effects could 
be explained by the modulation of the AMP-activated protein kinase signalling pathway. We show that 
both inhibitors cause mitochondrial alteration and an endoplasmic reticulum stress response. EB-3D 
and EB-3P exert effects on ChoKα expression, AMPK activation, apoptosis, endoplasmic reticulum 
stress and lipid metabolism. Taken together, results show that EB-3D and EB-3P have potential anti-
cancer activity through the deregulation of lipid metabolism.
Cancer is characterized by uncontrolled cell growth due to unrestrained proliferation and decreased apoptosis, 
as well as greater migration of cells capable of invading adjacent tissues and organs. That this disease is currently 
a leading cause of death worldwide, often due to chemotherapy resistance, highlights the urgency to seek new 
strategies and new drugs to fight the disease1. Each cancer is characterized by specific alterations that hamper 
developing a single strategy to combat them all. However, an alteration common to many types of cancer is an 
aberrant lipid metabolism. Thus, lipid metabolism may serve as a starting point for designing and developing 
new anticancer drugs2,3. In this way, in tumour cells and tumour progression, phospholipid biosynthesis is greater 
than in normal tissue4,5 and, more specifically, phosphocholine (PCho), and phosphatidylcholine (PC) levels rise 
in different cancers6–8. Furthermore, overexpression of the choline kinase α (ChoKα) isoform has been found 
in malignant cells and tumours of the liver, lung, colon, breast, prostate, and ovaries [Reviewed in6]. All such 
evidence makes the metabolism of choline and related compounds a metabolic hallmark associated with tumour 
onset and progression as well as the development of chemoresistance9,10. In this context, ChoKα has emerged as a 
marker for cancer progression and also as one of the most promising therapeutic target enzymes9,11.
ChoK participates in the biosynthesis of PC via CDP-choline, known as the Kennedy’s pathway12. First, cho-
line enters the cells through several transporters6,13 and then can be phosphorylated to form PCho by ChoK 
activity. PCho is then activated to CDP-choline by CTP:phosphocholine cytidylyltransferase, and finally choline 
phosphotransferase catalyses the transfer of PCho to DAG to produce PC. In addition to participating in the 
biosynthesis of PC, ChoK also has other functions in regulating cell-signalling pathways. For example, it has 
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been shown that downregulation of ChoKα attenuates the MAPK and PI3K/AKT signalling, which have been 
associated with cell proliferation14.
Given that ChoKα inhibition was considered to be of interest for inhibiting the growth and the invasive 
tumour phenotype, several laboratories began to synthesise compounds able to inhibit this enzyme. The first, 
hemicholinium-3, in addition to the inhibition of ChoKα activity blocks the sodium-dependent transport of 
choline and the synthesis of acetylcholine, with a high degree of side effects (Reviewed in15). Subsequently, 
bis-pyridinium (represented by MN58b) and bis-quinolinium (represented by RSM-932A) derivatives were 
synthesised, showing low or reduced toxicity in human tumours (Reviewed in16). Taking the MN58b and 
RSM-932A as patterns, and carrying out a detailed modelling study, we synthesised a series of new symmet-
rical biscationic compounds with the aim of increasing their polarity and solubility, improving inhibition of 
ChoKα enzyme, and consequently strengthening the antiproliferative effect on tumour-cell lines17. Among these, 
1,1′-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene)), bis(methylene))-bispyridinium, or–bisquinolinium bromide, 
EB-3D, and EB-3P (Fig. 1A), respectively, as demonstrated in our laboratory, inhibited ChoKα activity in a low 
micromolar range17. Docking studies executed on both crystal structures, i.e. ChoKα 1/2 (PDB ID: 4BR3) and 
ChoKα 1/4 (PDB ID: 4CG8), showed that the two compounds could adopt a synclinal conformation of the linker, 
1,2-dioxoethane fragment, which enabled it to be completely inserted into the enzyme.
Taking into account that ChoKα has become an attractive anticancer target, we analysed the cellular events 
triggered after treatment with the ChoKα inhibitors EB-3D and EB-3P and the underlying molecular mecha-
nisms, paying attention to cell-death pathways closely related to PC and cholesterol metabolism. It is well known 
that compounds that affect phospholipid metabolism also alter cholesterol homeostasis, cholesterol metabolism 
being key in the decision-making process between cell proliferation and differentiation18–20. The study focuses 
on the HepG2 cell line, which retains many of the metabolic features of human hepatocytes and thus serves as an 
excellent model to study lipid metabolism21.
Results
EB-3D and EB-3P inhibit cell growth in HepG2 cells. The antiproliferative effect of EB-3D and EB-3P 
has been demonstrated in several cell lines17, but data are still unavailable for hepatic tumour cells. For an evalua-
tion of the effect of these compounds on HepG2 cell proliferation, cells were incubated in the absence or presence 
of the inhibitors at concentrations of up to 40 μM for 48 h. The GI50 (half-maximal growth inhibitory concentra-
tion) value derived from the growth-inhibition curve of HepG2 cells were of 14.55 ± 2.13 and 4.81 ± 1.07 μM for 
EB-3D and EB-3P, respectively (Fig. 1B). This antiproliferative action could not be attributed to lysis as measured 
by LDH release into the medium (data not shown). The results demonstrate that in this cell line, the bisquinolin-
ium derivative EB-3P had higher antiproliferative activity than did the bispyridinium compound EB-3D.
Interference of EB-3D and EB-3P in phosphatidylcholine metabolism. We examined the effect of 
EB-3D and EB-3P on the biosynthesis of PC by using choline as exogenous precursor. As expected, both EB-3D 
and EB-3P clearly inhibited the incorporation of radiolabelled choline into the final product of the biosynthetic 
pathway, the PC. Thus, as reflected in Fig. 2A, exposure of HepG2 cells to both synthetic compounds resulted 
Figure 1. (A)Chemical structure of synthetic ChoKα inhibitors EB-3P and EB-3D. (B) Effects of EB-3D and 
EB-3P on HepG2 cell proliferation. HepG2 cells growing in the log phase were incubated with MEM/10% 
FBS in the presence or absence of different concentrations of ChoKα inhibitors for 48 h. Cell number was 
determined by crystal-violet staining and expressed as a percentage of the control cells. These experiments were 
performed twice in triplicate. *P< 0.0001.
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in a dose-dependent reduction of choline incorporation into PC. The effects of EB-3P and EB-3D on choline 
incorporation were similar, with IC50 values of approximately 5 μM. Since transfer of PCho from PC to ceramide 
produces sphingomyelin (SM), the labelling of SM was also determined under the same conditions. Figure 2B 
shows that both EB-3P and EB-3D depress SM synthesis, although this effect proved significant only at amounts 
higher than 1 μM of the drugs.
Inhibition of choline uptake by EB-3D and EB-3P. We also analysed the choline uptake in the HepG2 
cell line. According to our results, in cells treated for 24 h with the inhibitors, choline uptake was strongly inhib-
ited, registering IC50 values of 0.14 ± 0.01 μM for EB-3P and 1.21 ± 0.14 μM for EB-3D (Fig. 2C). Also, inhibition 
of choline uptake was detectable after 10 min of incubation with the inhibitors, as reflected in Fig. 2D. In any case, 
the action of EB-3P inhibitor is clearly stronger than that of EB-3D.
Figure 2. Effects of EB-3D and EB-3P on [methyl-14C]choline incorporation into phospholipids, choline 
uptake and ChoKα protein levels in HepG2 cells. Log-phase HepG2 cells were incubated with ChoKα inhibitors 
as described in Methods section. The incorporation of choline into PC (A) and SM (B) is expressed as nmol 
of choline incorporated per mg of cell protein. Choline uptake was determined in cells treated for 24 h (C) 
or 10 min (D) and expressed as a percentage of the control cells. Results represent the mean ± SEM of three 
independent experiments conducted in triplicate. *P < 0.05, **P < 0.001 when compared with control values. 
In E) it is represented the protein levels of ChoKα normalized to their respective β-actin level and expressed 
as x-fold change compared with the corresponding control ratio (1.0). The Western blot image shows a 
representative experiment repeated three times.
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Exposure to EB-3D and EB-3P affects the expression of ChoKα. Figure 2E represents images of 
ChoKα expression levels from HepG2 cells. To investigate the effect of EB-3D and EB-3P on ChoKα protein 
levels, we treated cells with inhibitors, and cell lysates were prepared as described in Methods section. Treatment 
of HepG2 cells with EB-3D or EB-3P resulted in a 23% or 42% lowering of ChoKα protein levels, respectively.
In addition, we determined the effect that EB-3D and EB-3P exert on the PC levels. As might be expected, the 
inhibitors significantly lowered the PC levels in HepG2 cells (Table 1). EB-3P reduced the amount of PC by 15 
and 31% at 10 and 30 μM, respectively, whereas EB-3D resulted in a minor inhibition (c. 14% at 10 and 30 μM).
Interference of EB-3D and EB-3P in phospholipid and neutral lipid metabolism. We used radi-
olabelled glycerol as an exogenous precursor to explore the effects of EB-3D and EB-3P on both phospholipid 
and neutral lipid biosynthesis. Both inhibitors markedly reduced the incorporation of glycerol into PC and phos-
phatidylethanolamine (PE) (Fig. 3). Thus, it is not surprising that the biosynthesis of phosphatidylserine (PS), a 
phospholipid synthesised via a base-exchange reaction that converts pre-existing phospholipids (i.e. PC and PE) 
into PS (Reviewed in22) was clearly reduced in treated cells (Fig. 3A,B). Notably, the biosynthesis of the neutral 
lipids triacylglycerol (TAG) and DAG also was markedly affected by both EB-3P and EB-3D in a dose-dependent 
manner. In this case, however, EB-3D appeared to be more strongly inhibitor, registering IC50 values of less than 
1 μM, which are clearly lower than those of EB-3P in HepG2-treated cells (Fig. 3C,D).
nmol PC/mg of protein
Control 154,43 ± 2,79
EB-3P
10 μM 128,47 ± 2,05a
30 μM 106,18 ± 4,12b
EB-3D
10 μM 133,63 ± 2,65b
30 μM 131,66 ± 7,60a
Table 1. Effects of EB-3D and ED-3P on PC levels. Log-phase HepG2 cells were incubated with ChoKα 
inhibitors for 48 h. Levels of PC were determined as described in methods section. The results are expressed as 
nmol of PC per mg of cell protein and represent the mean ± SEM of two independent experiments conducted in 
triplicate. aP < 0.05 bP < 0.005 when compared with control values.
Figure 3. Effects of EB-3D and EB-3P on [2-3H]glycerol incorporation into lipids in HepG2 cells. Log-phase 
HepG2 cells were exposed to ChoKα inhibitors for 24 h. Then, cells were incubated with [2-3H]glycerol as 
described in Methods section. The incorporation of glycerol into phospholipids (A,B) and neutral lipids (C,D) 
is expressed as nmol of glycerol incorporated per mg of cell protein and represent the mean ± SEM of two 
independent experiments conducted in triplicate. *P < 0.05 **P < 0.005 when compared with control values.
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Inhibition of cholesterol biosynthesis by EB-3D and EB-3P. To determine whether these inhibitors 
altered cholesterol metabolism, we measured cholesterol biosynthesis by the incorporation of radiolabelled ace-
tate into cholesterol. Notably, both inhibitors significantly affected the incorporation of acetate into cholesterol, 
showing a decrease in cholesterogenic activity. However, EB-3P was more potent (70% inhibition at 10 μM con-
centration), than EB-3D, showing 29% inhibition at the same concentration (Fig. 4A).
Exposure to EB-3D and EB-3P affects the expression of proteins related to cholesterol homeo-
stasis. These results led us to analyse the levels of the main proteins involved in cholesterol homeostasis, such 
as sterol regulatory element-binding protein 2 (SREBP-2), 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
(HMGCR) and LDL receptor (LDLR). Cholesterogenesis is known to be transiently induced by the transloca-
tion of the SREBP-2 transcription factor from the endoplasmic reticulum (ER) (126 kDa precursor form) to the 
nucleus (60 kDa mature form)23. High expression levels of the mature SREBP-2 were detected after treatment with 
ChoKα inhibitors when compared with basal levels in untreated cells, whereas the membrane-bound precursor 
form decreased in parallel with the appearance of the released mature form (Fig. 4B). This increase in the active 
form of SREBP-2 was accompanied by an increase in the expression of its targets, HMGCR and LDLR (Fig. 4C,D).
Alterations of autophagy-related proteins by EB-3D and EB-3P. Autophagy is an intracellular pro-
cess involved in the reutilizing of different cell components through the lysosomal pathway, a catabolic process 
that maintains cell homeostasis. In the present work we investigated the status of several autophagy-related fac-
tors, Beclin-1, microtubule-associated protein 1 light chain 3 (LC3), and p62, these being proteins that reflect the 
nucleation, elongation, and degradation stages of autophagy, respectively24. In our experiments, both inhibitors 
lowered Beclin-1 levels significantly at 24 h of exposure (Fig. 5A). Moreover, the conversion of LC3-I to LC3-II, 
the lipidated membrane-bound form, appears to be hindered by the inhibitors since the LC3-II/LC3-I ratio signif-
icantly decreased after HepG2 cells were exposed to inhibitors (Fig. 5B). In line with the above changes, the levels 
of p62 were significantly lower after the exposure of HepG2 cells to both EB-3D and EB-3P (Fig. 5C).
Figure 4. Effects of EB-3D and EB-3P on [1,2-14C]acetic acid incorporation into cholesterol and SREBP-
2, HMGCR and LDLR protein levels in HepG2 cells. Log-phase HepG2 cells were incubated with ChoKα 
inhibitors for 24 h. Then, cells were incubated with [1,2-14C]acetic acid as described in the Methods section. 
The incorporation of acetate into cholesterol (A) is expressed as nmol of acetate incorporated per mg of cell 
protein and represent the mean ± SEM of two independent experiments conducted in triplicate. *P < 0.05 when 
compared with control values. In (B) SREBP-2, (C) HMGCR and (D) LDLR are represented the protein levels 
normalized to their respective β-actin level and expressed as x-fold change compared with the corresponding 
control ratio (1.0). Western blots show a representative experiment repeated three times.
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Effects of inhibitors on apoptosis. We quantified the percentage of apoptosis in HepG2 cell cultures 
at basal levels and in the presence of the ChoKα inhibitors EB-3D and EB-3P. The apoptotic degree of HepG2 
cells after treatment with ChoKα inhibitors is shown in Fig. 6. Exposure to the inhibitory compounds revealed a 
higher percentage of early and late apoptosis. As can be seen, percentage of cells in apoptosis at basal levels was 
low due to the normal cell death in culture, which did not exceed 4%.
Effects of inhibitors on endoplasmic reticulum stress. To evaluate the effects of EB-3D and EB-3P on 
ER stress-signalling pathway, we determined levels of some proteins related to this process. HepG2 cells exposed to 
the drugs showed that CHOP/GADD153 (CCAAT/enhancer binding protein homologous transcription factor) and 
IRE1α (Inositol-requiring enzyme 1) protein levels significantly rose, as showed in Fig. 7A,B, respectively.
Effects of inhibitors on the mitochondrial membrane potential and intracellular reactive oxygen 
species production. Next, we analysed the effects of EB-3D and EB-3P on mitochondrial membrane potential 
(MMP) and oxidative stress in HepG2 cells. The results revealed that neither of the two inhibitors influenced ROS 
production (data not shown). However, MMP was significantly diminished, with EB-3P again being more potent 
(Fig. 7C). Carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone (FCCP) was used as a positive control for MMP.
Ultrastructural alterations produced by EB-3D and EB-3P. To analyse the possible morphological 
changes caused by EB-3D and EB-3P exposure, we used transmission electron microscopy (TEM) in control and 
HepG2-treated cells with 10 µM and 30 µM of both ChoKα inhibitors for 24 h. The results are shown in Fig. 8. 
In A) the untreated control cell shows mitochondria having a dense matrix, many cisternae of rough ER, and a 
small autophagic vacuole (AV) at the bottom of the micrography. In B) the morphology was not significantly 
affected by exposure to EB-3D 10 µM since the cells showed an appearance similar to that of controls. In C) the 
cells treated with EB-3D 30 µM underwent some dilatation of the ER cisternae and had a less dense mitochondrial 
matrix. The perinuclear space also showed a dilatation with an increasing separation between the two nuclear 
membranes. Exposure to EB-3P resulted in a more notable effect on the ultrastructure of HepG2 cells. Thus, in 
D) the treatment of the cells with 10 µM of this compound prompted notable dilatation of the ER, and the loss 
of mitochondrial density was also patent. The cell nucleus appeared lobulated with dense chromatinic bodies 
adhering to the inner nuclear membrane. In E), the treatment at the highest concentration (30 µM) increased 
the dilatation of ER cisternae, the rarefaction of mitochondria, and the enlargement of the perinuclear space. F) 
shows a detail indicating the dilatation of mitochondria with disorganised cristae, a less dense matrix and the 
ER cisternae with a notable dilatation of inner space, reflecting ER stress. G) shows HepG2 cells at the apoptotic 
stage induced by treatment with EB-3P. A picnotic nucleus is visible with many chromatinic bodies adhering 
Figure 5. Effects of EB-3D and EB-3P on (A) Beclin, (B) LC3 and (C) p62 protein levels. HepG2 cells were 
incubated without any additions (control) or ChoKα inhibitors for 24 h. Protein levels in the samples were 
normalized to their respective β-actin level and expressed as x-fold change compared with the corresponding 
control ratio (1.0). Western blots show a representative experiment repeated three times. Ratios between 
the intensity of the bands corresponding to LC3-II and LC3-I are shown (right panel). *P < 0.05, **P < 0.001 
compared to control value.
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Figure 6. Effect of EB-3D and EB-3P on apoptosis in HepG2 cells. HepG2 cells were incubated in the 
absence and presence of 30 μM ChoKα inhibitors or 0.5 μg·mL−1 staurosporine for 24 h. Cells were collected 
and analysed by flow-cytometry to determine apoptosis, as described in the Methods section. Figure shows 
representative flow-cytometry images of the control and treated cells. The percentages of each cell population 
are included in a table in which results are expressed as the mean ± SEM of three independent experiments 
conducted in triplicate. aP < 0.05, bP < 0.005 when compared with control values.
Figure 7. Effects of EB-3D and EB-3P on the expression of endoplasmic reticulum stress markers and on 
mitochondrial membrane potential in HepG2 cells. HepG2 cells were incubated without any additions or ChoKα 
inhibitors for 24 h. Protein levels of CHOP/GADD153 (A) and IRE1α (B) in the samples were normalized to 
their respective β-actin level and expressed as x-fold change compared with the corresponding control ratio (1.0). 
Western blots show a representative experiment repeated three times. For mitochondrial membrane potential 
determination we used JC-10 as described in Methods section. The ratio of red/green fluorescence intensity was 
used to determine the values of MMP. Results are expressed as the mean ± SEM of three independent experiments 
conducted in triplicate. *P < 0.05, **P < 0.001 when compared with control values.
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Figure 8. Ultrastructural alterations produced by ChoKα inhibitors. (A) Control HepG2 cells. (AV) 
Autophagic vacuole. (B) HepG2 cell exposed to EB-3D 10µM show ultrastructure similar to untreated cells. (C) 
Treatment with EB-3D 30 µM. Some dilatation of endoplasmic reticulum (ER) as well as of perinuclear space 
(Ps) is visible. (D) 24 h of exposure to EB-3P 10 µM. Cell shows a clear dilatation of ER cisternae and nuclear 
lobulation. (E) Treatment with EB-3P 30 µM increases the dilatation of ER. Ps is also dilated. (F) Detail of an 
EB-3P-treated cell showing wide ER cisternae and mitochondrial (M) rarefaction. (G) Cell in apoptotic stage 
induced by treatment with EB-3P. Picnotic nucleus (N), with many chromatinic bodies and perinuclear space 
notably dilated, is shown. Mitochondria are disorganised and great cytoplasmic vacuoles (V) appear as result of 
cell disorganization. Cell membrane (CM) rupture can be seen at some points.
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to the inner membrane and a notably dilated perinuclear space. The mitochondria look disorganized and great 
cytoplasmic vacuoles appear, as a result of cell disorganization. The cell membrane shows ruptures at some points.
EB-3D and EB-3P modulate the AMP-activated protein kinase signalling pathway. AMP-activated 
protein kinase (AMPK) is an intracellular energy-sensing kinase that is activated by AMP binding and phosphoryla-
tion of a threonine residue (Thr-172). To determine whether EB-3D and EB-3P were capable of modulate AMPK, we 
measured by Western blot the phosphorylation level of AMPK on HepG2 cells after 24 h of ChoKα inhibitor treat-
ment. The results indicate that both compounds significantly raised pAMPK levels and consequently the pAMPK/
AMPK ratio (Fig. 9). In addition, we determined the effect that EB-3D and EB-3P exert on the ATP levels. The inhib-
itors significantly lowered the ATP levels in HepG2 cells. EB-3P reduced the amount of ATP by 63 and 96% at 10 and 
30 μM, respectively, whereas EB-3D resulted in a minor inhibition (c. 19% at 10 and 61% at 30 μM).
Discussion
Lipids, required to maintain cell structure and provide energy, are also involved in cell signalling. Their metab-
olism generates a variety of biological intermediates that can regulate cell growth, proliferation, differentiation, 
survival, apoptosis, inflammation, and membrane homeostasis25,26. Disturbed lipid metabolism can cause diverse 
diseases, including a variety of cancers2.
Many tumours have been described to have an accelerated choline metabolism, the main consequence of 
which is a rise in the amount of choline-containing compounds6,8,15. In the last decade, with ChoKα consid-
ered an attractive target for novel anticancer therapies, a broad class of inhibitors of the isoenzyme ChoKα 
has been synthesised. Previously, we have reported that the bispyridinium and bisquinolinium derivatives of 
1,1′-(((ethane-1,2-diylbis(oxy))bis(4,1-phenylene))bis(methylene)) containing a pair of oxygen atoms in the 
linker of their structure, EB-3D and EB-3P, respectively, inhibited ChoKα activity with a similar value of IC50 
(1.00 ± 0.01 and 0.92 ± 0.01 μM, respectively), also exerting anti-neoplastic effects over an array of tumour-cell 
lines17. In the present work, we firstly evaluated the dose-dependent antiproliferative activity of these compounds 
against the HepG2 cell line. We selected this hepatoblastoma cell line for being an excellent model to study lipid 
metabolism21 and showing high mRNA-expression levels of ChoKα27. Our results indicate that HepG2 cells are 
less sensitive to EB-3D or EB-3P than are some other human tumour cells17, demonstrating that the extent of the 
cytotoxic effects of these agents depends upon the tumour-cell line.
The data compiled in the present work show that ChoKα inhibition by EB-3D or EB-3P depressed PC biosynthe-
sis through the CDP-choline pathway, this also leading to a marked inhibition of SM production. These results agree 
with the lower levels of PC detected in our study after treatment with inhibitors. However, since choline is essential 
for PC biosynthesis, the intracellular choline availability could also limit the synthesis of this phospholipid. Notably, 
as shown, choline uptake was markedly inhibited in the presence of both ChoKα inhibitors not only after 24 h of 
treatment but also after only 10 min of exposure of HepG2 cells. All together, our results support the conclusion 
that EB-3D and EB-3P inhibit both the ChoKα and the choline transport activity, and that the dual action of these 
compounds on both processes is associated with a lower level of PC and consequently diminished cell proliferation.
Several works demonstrate that ChoKα downregulation with siRNA significantly diminishes cell viability, 
suggesting that the ChoKα protein levels are in part responsible for altering cell viability9,10. In this sense, Mori 
et al.28 have published data on a selective ChoKα inhibitor, V-11-0711, which significantly lowered PCho levels 
but did not reduce cell viability as long as ChoKα protein and PC levels were not lowered. Notably, in our study 
EB-3D and EB-3P decreased ChoKα protein and lowered PC levels.
Figure 9. Effects of EB-3D and EB-3P on AMPK protein levels. HepG2 cells were incubated without any 
additions or ChoKα inhibitors for 24 h. The bands corresponding to pAMPK and total AMPK were scanned, 
and arbitrary units were assigned by densitometric analysis. The figure shows a representative experiment 
repeated three times (left panel). Ratios between the intensity of the bands corresponding to pAMPK and 
AMPK are shown and expressed as x-fold change compared with the corresponding control ratio (1.0) (right 
panel). *P < 0.05, **P < 0.001 compared to control value.
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Glycerol is a precursor of phosphatidate, a common intermediate in the synthesis of phospholipids and TAG. 
The use of glycerol as an exogenous substrate enables us to analyse the activity of both biosynthetic pathways 
simultaneously. As might be expected, EB-3D and EB-3P caused a significant decrease in the quantity of glycerol 
incorporated into phospholipids, as described in the Results section. This action was accompanied by a marked 
decrease in the incorporation of glycerol into TAG and DAG. This lower availability of DAG could in part con-
tribute to the decline in phospholipid synthesis observed in our study.
The importance of the PC and cholesterol synthesis pathways in tumour proliferation is evident from previous 
studies conducted by our research group18,20. No data are available concerning the effects of ChoKα inhibitors 
on the biosynthesis of cholesterol, and thus the results presented in this paper demonstrate for the first time that 
EB-3D and EB-3P decrease the de novo synthesis of cholesterol. However, of the two inhibitors tested, EB-3P 
exerted stronger effects on cholesterol synthesis. In any case, the simultaneous reduction in the cholesterogenesis 
and synthesis of choline-containing phospholipids found in this study agree with reports by several researchers 
indicating that the concentration of cholesterol and phospholipids containing choline are regulated in a coordi-
nated manner, since their relative proportions are essential in maintaining cell-membrane integrity19.
All these metabolic changes led us to investigate the status of AMPK, a cell-energy sensor activated in response 
to a variety of conditions that deplete cell energy29. This protein can also act as a metabolic tumour suppressor inhib-
iting cell growth in a wide variety of cancers30,31. In the present work, both EB-3D and EB-3P increases the phos-
phorylation and activation of AMPK in HepG2 cells. Actually, in our study, we found that both ChoKα inhibitors 
cause a concentration-dependent decrease in MMP not accompanied by an increase in ROS. In this way, as shown 
by TEM, mitochondria of HepG2-treated cells were clearly affected, showing disorganization and loss of density at 
the higher amount of inhibitors. The reduction of the MMP would depress ATP production and raise the AMP/
ATP ratio. This implies a decrease in cell-energy reserves and thus a possible additional cause for the inhibition of 
PC biosynthesis, mainly because ChoKα activity is quite sensitive to changes in ATP concentration32. Moreover, the 
AMPK activation stimulates the pathways that generate ATP, while biosynthetic processes such as cholesterol and 
TAG biosynthesis are inhibited, as observed in our study. In relation to cholesterol metabolism, it has been widely 
documented that activated AMPK phosphorylates and inactivates the limiting enzyme of cholesterol biosynthesis, 
HMGCR29. These data agree with the inhibition of cholesterol synthesis found in our study after ChoKα inhibitor 
treatments. Cholesterol biosynthesis is also transcriptionally regulated by SREBP-2. In the absence of cholesterol the 
mature SREBP-2 migrates to the nucleus and acts as a transcription factor to promote the expression of target genes 
involved in cholesterol biosynthesis and uptake, such as HMGCR and LDLR33. Data from our study indicate that the 
inhibition of HMGCR by AMPK could lead to an initial reduction of intracellular cholesterol, activating SREBP-2 
and increasing protein expression of its targets, HMGCR and LDLR, as occurs after statin treatment34. Moreover, 
our data agree with those of other authors35,36, who hold that AMPK activation leads to a compensatory increase in 
SREBP-2, and consequently in the transcripts of its target genes.
In addition to the importance of mitochondria in energy metabolism, they have also been recently shown 
to participate in regulating cell death. An alteration in MMP leads to the opening of pores in the mitochondria 
and the release of cytochrome c to the cytosol, which activates caspase-9. On being activated, caspase-9 in turn 
activates caspase-3, which triggers the last stages of apoptosis. The results from TEM and flow cytometry analyses 
reveal that HepG2 cells treated with inhibitors show an apoptotic process. However, we found that apoptosis 
induced by EB-3D or EB-3P cannot be attributed to a mechanism involving mitochondria-mediated pathways, 
since we did not detect caspase-3 activation (data not shown), suggesting caspase-independent cell death. It 
should be taken into account that apoptosis has also been linked to ER stress induction, as reported elsewhere37. 
It is well established that ChoKα inhibition in cancer cells induces ER stress and triggers apoptosis37–39. CHOP 
has been established as an acute ER stress marker40. In addition, IRE1α is ER stress sensor and is essential for 
the unfolded protein response and sufficient to trigger the apoptotic response41. Ultrastructural examination of 
HepG2 cells treated with both inhibitors revealed the well-characterised distortion of ER with cisternae that pre-
sents a notable dilatation of the inner space associated with ER stress. The results suggest that the drugs promote 
intensified ER stress response, sustained by CHOP and IRE1α production.
We have also investigated the possible involvement of another pathway of cell death, i.e. the autophagy on the 
EB-3D and EB-3P biological actions. As mentioned above, the fall in the levels of the autophagy-related proteins 
measured in our study clearly indicates that both EB-3D and EB-3P act as inhibitors of basal autophagy in HepG2 
cells. This contention is supported by the ultrastructural analysis in which no autophagosomes and autolysosomes 
were observed in HepG2-treated cells. It is evident that the impairment in basal autophagy could lead to an 
accumulation of long-lived proteins and damaged organelles. In addition to its conventional role in cell survival, 
autophagy can also be a death promoter42. We have previously demonstrated that autophagy in HepG2 cells has 
a pro-survival effect and that autophagy inhibition inhibits cell proliferation20. Hence, the inhibition of the basal 
autophagy caused by EB-3P and EB-3D might contribute to antiproliferative action of these compounds.
In summary, EB-3D and EB-3P have multifactorial effects: 1) the inhibition of ChoKα enzyme activity, 2) 
downregulation of ChoKα expression, 3) AMPK activation, 4) apoptosis dependent on ER stress, 5) inhibition 
of basal autophagy, and 6) deregulation of lipid metabolism. The disruption of phospholipid homeostasis is asso-
ciated with an alteration of cholesterol metabolism and cell survival. All these results indicate that EB-3D and 
EB-3P have a potential anti-cancer activity through the inhibition of lipid metabolism.
Methods
Materials. FBS and MEM were obtained from Biowest (Nuaillé, France). The TLC plates, protease-inhibitor 
cocktail, fluorimetric intracellular ROS kit, mitochondrial membrane potential kit, phosphatidylcholine assay 
kit, and caspase 3 assay kit were from Sigma-Aldrich (Madrid, Spain). The Muse Annexin V & Dead Cell Assay 
was from Merck Chemicals & Life Science (Madrid, Spain). [Methyl-14C]choline, [1,2-14C]acetic acid and [2-3H]
glycerol were from Perkin Elmer (Madrid, Spain). Mini-PROTEAN® TGX Stain-Free™ Protein Gels, Trans-Blot® 
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Turbo™ Mini PVDF and Clarity™ Western ECL substrate were from Bio-Rad Laboratories, Inc. (Madrid, Spain). 
Monoclonal anti-human primary antibody ChoKα and polyclonal β-actin were from Santa Cruz Biotechnology, 
Inc. (Heidelberg, Germany). Monoclonal anti-human primary antibodies (p62, AMPKα, Phospho-AMPKα, CHOP, 
IRE1α), polyclonal anti-human primary antibodies (LC3A/B and Beclin-1) and horseradish peroxidase (HRP)-
linked secondary IgGs were from Cell Signaling Technology (Danvers, MA, USA). Polyclonal anti-human antibody, 
SREBP-2, and monoclonal anti-human antibodies LDLR and HMGCR were from Abcam (Cambridge, MA, USA).
Cell culture. The human hepatoma HepG2 cell line was obtained from the European Collection of Animal 
Cell Cultures (Salisbury, UK). The cells were cultured in MEM containing 10% heat-inactivated FBS supple-
mented with 2 mM L-glutamine, 1% non-essential amino acids, 100 U·mL−1 penicillin and 100 μg·mL−1 strepto-
mycin, in a humid atmosphere with 5% CO2 at 37 °C, and subcultured at a ratio of 1:10 once a week.
Cell proliferation assay. HepG2 cells were seeded onto 96-well plates (10,000 cells/well) and maintained 
in MEM containing 10% FBS for 24 h. Then, the culture medium was replaced with fresh medium/10% FBS and 
the cells were incubated up to 48 h in the absence or presence of different amounts of ChoKα inhibitors before 
analyses. The antiproliferative effect of the distinct compounds was assessed by the crystal violet-staining assay 
using a cell-number-based standard curve as previously reported43. The absorbance of crystal violet in each well 
was measured at a wavelength of 590 nm directly in plates using a microplate reader (HTX Microplate Reader 
BioTek Instruments, Vermont, USA).
Choline uptake assay. Choline uptake was determined as previously reported44. Briefly, HepG2 cells were 
incubated for 10 min or 24 h at 37 °C either in a medium containing different concentrations of ChoKα inhibi-
tors or with no supplement as controls. The medium was then removed and the cells immediately exposed to a 
medium containing [methyl-14C]choline (16 μM, 31 Ci·mol−1) for 5 min at 37 °C. The incorporation of choline 
was stopped by medium aspiration followed by two washes with ice-cold PBS containing 580 µM choline. The 
cells were solubilized in NaOH 0.1 N and an aliquot used to determine the total amount of radiolabel taken up 
by the cells.
Metabolic labelling assays. Cells were incubated both in the presence and absence of different amounts 
of ChoKα inhibitors for 24 h. Either [methyl-14C]choline (60 μM, 27 Ci·mol−1), [1,2-14C]acetic acid (35 μM, 
29 Ci·mol−1) or [2-3H]glycerol (25 μM, 80 Ci·mol−1) were added during the last 4 h of the incubation period. Lipid 
biosynthetic activity was estimated according to the level of incorporation of the radiolabel of each exogenous 
precursor into the corresponding lipid. Lipids were extracted from the cells following the procedure of Bligh and 
Dyer45. The different phospholipids were separated on silica-gel 60 G TLC plates using a mixture of chloroform/
methanol/acetic acid/water (60:50:1:4, v/v) as a solvent, and neutral lipids were separated by TLC using a solvent 
of n-hexane/ethyl ether/acetic acid (80:20:2, v/v). The lipid spots were made visible by exposure to iodine vapour, 
and the scraped spots were radiometrically measured by liquid scintillation using a Beckman 6000-TA counter 
(Madrid, Spain).
Immunoblotting analysis. Cells growing in the log phase were incubated for 24 h with MEM/10% FBS in 
the absence or presence of 30 μM of the assayed compounds. The cells were washed twice, scraped into ice-cold 
PBS (pH 7.4) and centrifuged at 100 × g for 10 min at 4 °C. The cell pellets were suspended in 0.1 mL ice-cold lysis 
buffer consisting of 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100 and a protease inhibitor cocktail, 
and incubated on ice for 30 min with occasional shaking. Cell lysates were centrifuged at 10,000 × g for 15 min 
at 4 °C and supernatants were stored at −80 °C until used; an aliquot was taken to determine the protein concen-
tration. Equal amounts of lysate protein were separated by SDS-PAGE and transferred onto PVDF membranes. 
Pre-stained protein molecular-weight markers were used during electrophoresis. Membranes were blocked in 
TBS containing 5% non-fat dried milk and 0.05% Tween-20 for 1 h, and then probed with anti-human primary 
Igs (1:1,000) in 3% BSA-blocking buffer at 4 °C overnight. After several washes in TBS containing 0.05% Tween-
20, the membranes were incubated with the corresponding HRP-conjugated IgG (1:2,000) as a secondary anti-
body for 1 h. Immunoreactive proteins were detected using ECL substrate and the membranes were imaged using 
the Molecular Imager ChemiDocTM MP System (Bio-Rad Laboratories, Inc., Madrid, Spain). Following incu-
bation with an antibody-stripping solution consisting of 60 mM Tris-HCl (pH 6.8), 100 mM β-mercaptoethanol 
and 2% SDS for 30 min at 60 °C, the blots were probed with polyclonal anti-human β-actin (1:1,000) to monitor 
the loading and transfer of the blotted samples. Densitometric analyses were carried out using ChemiDocTM MP 
System software.
Mitochondrial membrane potential assay. The MMP was determined by using the fluorescent probe 
JC-10 dye following the manufacturer’s recommendations. Briefly, cultured cells were exposed up to 30 µM 
ChoKα inhibitors for 24 h or to 1 μM FCCP for 2 h as a positive control. After this incubation period, JC-10 
dye solution was added to each sample and the fluorescence intensity (λex = 490/λem = 525 nm) and (λex = 540/
λem = 590 nm) was monitored. Mitochondrial depolarization is indicated by a decrease in the red/green fluores-
cence intensity ratio.
Apoptosis assay. The induction of apoptosis was determined by flow cytometry using the Annexin V and 
Dead Cell kit. HepG2 cells were incubated for 24 h either in a medium containing 30 µM ChoKα inhibitors or 
with no supplement as controls. Staurosporine (0.5 µg·mL−1) was used as a positive control. This kit is based on 
the detection of PS, on the surface of apoptotic cells, by a reagent containing fluorescently labelled Annexin V 
and 7-amino-actinomycin (7-AAD). This kit can distinguish between four cell populations: viable cells (Annexin 
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V− and 7-AAD−), early apoptotic cells (Annexin V+ and 7-AAD−), late apoptosis or dead cells (Annexin V+ and 
7-AAD+) and necrotic cells (Annexin V− and 7-AAD+).
Transmission electron microscopy. HepG2 cells were plated in six-well dishes and allowed to grow for 
24 h. A vehicle (control) or 10 and 30 µM EB-3D or EB-3P was added for 24 h. Cells were collected using trypsin 
and centrifuged at 1,500 r.p.m. for 5 min in MEM/10% FBS. Cell pellets were fixed in 2.5% glutaraldehyde +2% 
paraformaldehyde in 0.05 M cacodylate buffer for 4 h at 4 °C. The samples were washed three times with caco-
dylate buffer and postfixed in an aqueous solution of 1% OsO4 containing 1% potassium ferrocyanide for 1 h at 
4 °C in darkness. The following washes were done: 0.15% tannic acid in cacodylate buffer, cacodylate buffer, and 
H2O, all at room temperature. The samples were left in 2% uranyl acetate for 2 h and washed several times with 
H2O. Dehydration in ethanol solutions rising from 50% to 100% was done at 4 °C. The samples were embedded in 
resin (EMbed 812/100% ethanol (1/1)) for 60 min at room temperature, the same resin at a 2/1 ratio for 60 min, 
and then resin without ethanol overnight. For polymerization, the samples were incubated in pure resin for 48 h at 
60 °C. Ultrafine sections (50–70 nm) were cut using a Leica Ultramicrotome R and contrasted using 1% aqueous 
uranyl acetate for 5 min and lead citrate in a CO2-depleted atmosphere for 4 min46. A Zeiss Libra Plus 120 electron 
microscope was used to visualise the sections.
other analyses. The intracellular ROS were determined by using the fluorimetric intracellular ROS kit fol-
lowing the manufacturer’s recommendations. This kit provides a fluorogenic sensor which react with ROS, result-
ing in a fluorometric product proportional to the amount of ROS present in live cells. The assay was performed in 
96 multiwell plates, with detection at λex = 650/λem = 675 nm.
The levels of PC were quantified following the manufacturer’s instructions for the PC levels kit after treatment 
of cells with or without inhibitors.
The caspase 3 fluorimetric assay kit was used to measure caspase 3 activity in cell extracts. The peptide sub-
strate of this kit, acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin, is hydrolyzed in the presence of caspase 
3 resulting in the release of the fluorescent 7-amino-4-methylcoumarin moiety, which is detected at λex = 360/
λem = 460 nm.
ATPlite assay kit from PerkinElmer was used to determine the intracellular levels of ATP. This kit is based on 
the generation of luminescence initiated by the reaction of ATP with luciferase and D-luciferin.
Protein concentrations were determined by the Bradford’s method47 using BSA as standard.
Statistics. The results are expressed as means ± SEM. A one-way ANOVA was conducted with post hoc com-
parisons by Scheffé’s test (SPSS 13.0). P < 0.05 is considered statistically significant.
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